Jeremy Levin

Jeremy Levin
Biotech

Ovid staff shuffle reads like a who's who of Big Pharma

Ovid Therapeutics has announced a leadership shuffle and staff reductions as it pivots to focus on early-stage development.
Annalee Armstrong Jul 9, 2021 9:50am
Jeremy Levin - Credit Kelly Boothe agent of Ovid Therapeutics - Own work - CC BY-SA 40

Ovid plans to shop with Takeda bucks after shedding lead asset

Apr 22, 2021 9:50am
Takeda US facility

Takeda brings an epilepsy med back into the fold

Mar 3, 2021 7:00am
Jeremy Levin - Credit Kelly Boothe agent of Ovid Therapeutics - Own work - CC BY-SA 40

Ovid flunks Angelman phase 3, leaving field wide open for rivals

Dec 2, 2020 7:56am
Jeremy Levin - Credit Kelly Boothe agent of Ovid Therapeutics - Own work - CC BY-SA 40

Takeda, Ovid plot next steps for rare epilepsy med

Sep 30, 2020 8:00am
Jeremy Levin - Credit Kelly Boothe agent of Ovid Therapeutics - Own work - CC BY-SA 40

Angelini lands EU rights to Ovid's phase 3 rare disease drug

Jul 13, 2020 7:00am